Integral Health Asset Management LLC Purchases 50,000 Shares of BioNTech SE (NASDAQ:BNTX)

Integral Health Asset Management LLC grew its position in BioNTech SE (NASDAQ:BNTX - Free Report) by 100.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 100,000 shares of the company's stock after acquiring an additional 50,000 shares during the period. Integral Health Asset Management LLC's holdings in BioNTech were worth $11,395,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of BNTX. Jones Financial Companies Lllp raised its stake in shares of BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares during the last quarter. Quintet Private Bank Europe S.A. raised its stake in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after acquiring an additional 700 shares during the last quarter. Allianz SE bought a new position in shares of BioNTech in the fourth quarter valued at approximately $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech in the fourth quarter valued at approximately $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech in the fourth quarter valued at approximately $168,000. Institutional investors own 15.52% of the company's stock.

BioNTech Stock Up 0.5%

NASDAQ BNTX traded up $0.43 on Friday, reaching $92.77. The company had a trading volume of 733,409 shares, compared to its average volume of 932,507. The firm has a market capitalization of $22.30 billion, a price-to-earnings ratio of -44.18 and a beta of 1.35. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The company's fifty day moving average is $97.41 and its 200-day moving average is $108.84.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period in the prior year, the business earned $1.90 EPS. On average, research analysts forecast that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently weighed in on BNTX. Canaccord Genuity Group reissued a "buy" rating and issued a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. BMO Capital Markets raised their price target on shares of BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $134.00 price target (down previously from $145.00) on shares of BioNTech in a report on Wednesday. Citigroup reaffirmed a "buy" rating and set a $140.00 target price (down previously from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Finally, Morgan Stanley lowered their target price on shares of BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $142.08.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.